Bevacizumab for metachronous metastatic colorectal cancer: a reflection of community based practice

L. G. E. M. Razenberg, Y. R. B. M. van Gestel, Ignace H. J. T. de Hingh, Olaf J. L. Loosveld, G. Vreugdenhil, Laurens V. Beerepoot, G.J. Creemers, Valery E. P. P. Lemmens

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Article number110
Pages (from-to)1-9
Number of pages9
JournalBMC Cancer
Volume16
DOIs
Publication statusPublished - 16 Feb 2016

Keywords

  • Colorectal cancer
  • Metachronous metastases
  • Palliative
  • Chemotherapy
  • Targeted therapy
  • Bevacizumab

Cite this

Razenberg, L. G. E. M., van Gestel, Y. R. B. M., de Hingh, I. H. J. T., Loosveld, O. J. L., Vreugdenhil, G., Beerepoot, L. V., Creemers, G. J., & Lemmens, V. E. P. P. (2016). Bevacizumab for metachronous metastatic colorectal cancer: a reflection of community based practice. BMC Cancer, 16, 1-9. [110]. https://doi.org/10.1186/s12885-016-2158-8